Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: Implications for MET targeting in oncology

Future Oncology

Volumn 10, Issue 2, 2014, Pages 211-217

  Stutz, Emanuel ^a   Gautschi, Oliver ^a,b   Fey, Martin F ^a,c   Gugger, Mathias ^a   Tschan, Mario P ^a,c   Rothschild, Sacha I ^a,d  

^a UNIVERSITY OF BERN   (Switzerland)

^b LUZERNER KANTONSSPITAL   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

ALK; crizotinib; ID1; lung cancer; MET; migration

Indexed keywords

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; PYRAZOLES; PYRIDINES;

EID: 84893856319     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.179     Document Type: Article

References (31)

1. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 68, 3077-3080; discussion 80 (2008).
2. Bronte G, Rizzo S, La Paglia L et al. Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat. Rev. 36(Suppl. 3), S21-S29 (2010).
3. Garber K. ALK, lung cancer, and personalized therapy: portent of the future? J. Natl Cancer Inst. 102, 672-675 (2010).
4. Janku F, Stewart DJ, Kurzrock R. Targeted therapy in non-small-cell lung cancer-is it becoming a reality? Nat. Rev. Clin. Oncol. 7, 401-414 (2010).
5. Scagliotti G, Stahel RA, Rosell R et al. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development. Eur. J. Cancer 48, 961-973 (2012).
6. Soda M, Choi YL, Enomoto M et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448, 561-566 (2007). (Pubitemid 47206930)
7. Zou HY, Li Q, Lee JH et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive anti-tumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67, 4408-4417 (2007). (Pubitemid 46815090)
8. Kwak EL, Camidge DR, Clark J et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J. Clin. Oncol. 27(Suppl.), Abstract 3509 (2009).
9. Kwak EL, Bang YJ, Camidge DR et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
10. Shaw AT, Yeap BY, Solomon BJ et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
11. Shaw AT, Kim DW, Nakagawa K et al. Phase III Study of Crizotinib versus Pemetrexed or Docetaxel Chemotherapy in Patients with advanced ALK-positive Non-Small Cell Lung Cancer (NSCLC) (PROFILE 1007). Ann. Oncol. 23(Suppl. 9), Abstract LBA1-PR (2012).
12. Tanizaki J, Okamoto I, Okamoto K et al. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential anti-tumor effects in non-small cell lung cancer according to MET alterations. J. Thorac. Oncol. 6, 1624-1631 (2011).
13. Ou SH, Kwak EL, Siwak-Tapp C et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J. Thorac. Oncol. 6, 942-946 (2011).
14. Yasuda H, de Figueiredo-Pontes LL, Kobayashi S et al. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J. Thorac. Oncol. 7, 1086-1090 (2012).
15. Bergethon K, Shaw AT, Ou SH et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
16. Zillhardt M, Christensen JG, Lengyel E. An orally available small-molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis. Neoplasia 12, 1-10 (2010).
17. Okamoto W, Okamoto I, Arao T et al. Anti-tumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol. Cancer Ther. 11, 1557-1564 (2012).
18. Lennerz JK, Kwak EL, Ackerman A et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J. Clin. Oncol. 29, 4803-4810 (2011).
19. Shojaei F, Simmons BH, Lee JH et al. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320, 48-55 (2012).
20. Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell. Biol. 18, 516-523 (2006). (Pubitemid 44332916)
21. Yoshida T, Okamoto I, Okamoto W et al. Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification. Cancer Sci. 101, 167-172 (2010).
22. Sen B, Peng S, Saigal B et al. Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer. Clin. Cancer Res. 17, 514-524 (2011).
23. Gautschi O, Tepper CG, Purnell PR et al. Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer Res. 68, 2250-2258 (2008). (Pubitemid 351521798)
24. Benezra R, Davis RL, Lockshon D et al. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 61, 49-59 (1990).
25. Rothschild SI, Kappeler A, Ratschiller D et al. The stem cell gene 'inhibitor of differentiation 1' (ID1) is frequently expressed in non-small cell lung cancer. Lung Cancer 71, 306-311 (2011).
26. Rothschild SI, Tschan MP, Federzoni EA et al. MicroRNA-29b is involved in the Src-ID1 signaling pathway and is dysregulated in human lung adenocarcinoma. Oncogene 31, 4221-4232 (2012).
27. Rothschild SI, Tschan MP, Jaggi R et al. MicroRNA-381 represses ID1 and is deregulated in lung adenocarcinoma. J. Thorac. Oncol. 7, 1069-1077 (2012).
28. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402-408 (2001). (Pubitemid 34164012)
29. Purnell PR, Mack PC, Tepper CG et al. The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. J. Thorac. Oncol. 4(4), 448-454 (2009).
30. Kohanka A, Barti-Juhasz H, Schönleber J et al. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer 83(1), 109-111 (2014).
31. Tschan MP, Fischer KM, Fung VS et al. Alternative splicing of the human cyclin D-binding Myb-like protein (hDMP1) yields a truncated protein isoform that alters macrophage differentiation patterns. J. Biol. Chem. 278, 42750-42760 (2003). (Pubitemid 37345884)